Cargando…

The Differential Effects of Anti-Diabetic Thiazolidinedione on Prostate Cancer Progression Are Linked to the TR4 Nuclear Receptor Expression Status()()

The insulin sensitizers, thiazolidinediones (TZDs), have been used as anti-diabetic drugs since the discovery of their ability to alter insulin resistance through transactivation of peroxisome proliferator-activated receptors (PPARs). However, their side effects in hepatitis, cardiovascular diseases...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Shin-Jen, Lin, Chang-Yi, Yang, Dong-Rong, Izumi, Kouji, Yan, Emily, Niu, Xiaodan, Chang, Hong-Chiang, Miyamoto, Hiroshi, Wang, Nancy, Li, Gonghui, Chang, Chawnshang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415117/ https://www.ncbi.nlm.nih.gov/pubmed/25925376 http://dx.doi.org/10.1016/j.neo.2015.02.005

Ejemplares similares

TR4 Nuclear Receptor Different Roles in Prostate Cancer Progression
por: Lin, Shin-Jen, et al.
Publicado: (2015)

TR4 nuclear receptor enhances prostate cancer initiation via altering the stem cell population and EMT signals in the PPARG-deleted prostate cells
por: Lin, Shin-Jen, et al.
Publicado: (2015)

Reduced osteoblast activity in the mice lacking TR4 nuclear receptor leads to osteoporosis
por: Lin, Shin-Jen, et al.
Publicado: (2012)

Targeting TR4 nuclear receptor suppresses prostate cancer invasion via reduction of infiltrating macrophages with alteration of the TIMP-1/MMP2/MMP9 signals
por: Ding, Xianfan, et al.
Publicado: (2015)

TR(4) nuclear receptor suppresses HCC cell invasion via downregulating the EphA2 expression
por: Jin, Ren’an, et al.
Publicado: (2018)

Correction to: Targeting TR4 nuclear receptor suppresses prostate cancer invasion via reduction of infiltrating acrophages with alteration of the TIMP-1/MMP2/MMP9 signals
por: Ding, Xianfan, et al.
Publicado: (2020)

TR4 nuclear receptor increases prostate cancer invasion via decreasing the miR-373-3p expression to alter TGFβR2/p-Smad3 signals
por: Qiu, Xiaofu, et al.
Publicado: (2015)

Deficiency in TR4 nuclear receptor abrogates Gadd45a expression and increases cytotoxicity induced by ionizing radiation
por: Yan, Shian-Jang, et al.
Publicado: (2012)

TR4 nuclear receptor enhances the cisplatin chemo-sensitivity via altering the ATF3 expression to better suppress HCC cell growth
por: Shen, Jiliang, et al.
Publicado: (2016)

Targeting TR4 nuclear receptor with antagonist bexarotene increases docetaxel sensitivity to better suppress the metastatic castration-resistant prostate cancer progression
por: Hu, Linyi, et al.
Publicado: (2019)

Targeting inflammatory cytokines-androgen receptor (AR) signaling with ASC-J9(®) to better battle prostate cancer progression
por: Izumi, Kouji, et al.
Publicado: (2013)

The roles of testicular nuclear receptor 4 (TR4) in male fertility-priapism and sexual behavior defects in TR4 knockout mice
por: Collins, Loretta L, et al.
Publicado: (2011)

New therapy with ASC-J9(®) to suppress the prostatitis via altering the cytokine CCL2 signals
por: Lin, Shin-Jen, et al.
Publicado: (2016)

Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation
por: Izumi, Kouji, et al.
Publicado: (2013)

Metformin Inhibits Nuclear Receptor TR4–Mediated Hepatic Stearoyl-CoA Desaturase 1 Gene Expression With Altered Insulin Sensitivity
por: Kim, Eungseok, et al.
Publicado: (2011)

Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression
por: Shi, Hangchuan, et al.
Publicado: (2019)

Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression
por: Chou, Fu-Ju, et al.
Publicado: (2019)

Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke
por: Ahn, Chang Ho, et al.
Publicado: (2019)

Thiazolidinediones are partially effective bitter blockers
por: Nguyen, Ha, et al.
Publicado: (2023)

Targeting the TR4 nuclear receptor with antagonist bexarotene can suppress the proopiomelanocortin signalling in AtT‐20 cells
por: Xia, Liqun, et al.
Publicado: (2021)

Glycemic Control with Thiazolidinedione Is Associated with Fracture of T2DM Patients
por: Chen, Hsin-Hung, et al.
Publicado: (2015)

The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer
por: Wang, Keliang, et al.
Publicado: (2020)

Chemotherapy and Chemoprevention by Thiazolidinediones
por: Fröhlich, Eleonore, et al.
Publicado: (2015)

Thiazolidinediones and bone fractures
por: Kaku, Kohei, et al.
Publicado: (2011)

BM-MSCs promote prostate cancer progression via the conversion of normal fibroblasts to cancer-associated fibroblasts
por: WEN, SIMENG, et al.
Publicado: (2015)

The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals
por: Xu, Junjie, et al.
Publicado: (2016)

Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention
por: Horita, Shoko, et al.
Publicado: (2015)

Use of thiazolidinediones and risk of hip fracture in old people in a case–control study in Taiwan
por: Lin, Hsien-Feng, et al.
Publicado: (2017)

Role of thiazolidinediones, insulin sensitizers, in non‐alcoholic fatty liver disease
por: Chang, Eugene, et al.
Publicado: (2013)

Thiazolidinediones: the Forgotten Diabetes Medications
por: Lebovitz, Harold E.
Publicado: (2019)

Potential Therapeutic Effects of Thiazolidinedione on Malignant Glioma
por: Sheu, Meei-Ling, et al.
Publicado: (2022)

Thiazolidinediones and Risk of Long-Term Dialysis in Diabetic Patients with Advanced Chronic Kidney Disease: A Nationwide Cohort Study
por: Chen, Yu-Hsin, et al.
Publicado: (2015)

Sorafenib with ASC‐J9(®) synergistically suppresses the HCC progression via altering the pSTAT3‐CCL2/Bcl2 signals
por: Xu, Junjie, et al.
Publicado: (2016)

Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells
por: Lin, Changyi, et al.
Publicado: (2020)

Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression
por: Klopper, Joshua P, et al.
Publicado: (2009)

The orphan nuclear receptor small heterodimer partner is required for thiazolidinedione effects in leptin-deficient mice
por: Tseng, Hsiu-Ting, et al.
Publicado: (2015)

Thiazolidinedione induced thyroid associated orbitopathy
por: Lee, Seongmu, et al.
Publicado: (2007)

Risk of Fracture with Thiazolidinediones: Disease or Drugs?
por: Bazelier, Marloes T., et al.
Publicado: (2012)

Therapeutic Actions of the Thiazolidinediones in Alzheimer's Disease
por: Pérez, María José, et al.
Publicado: (2015)

Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals
por: Deng, Gang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kb7ucus85m3j6c1v5avqthejff